Slowing Disease Progression is a Significant Triumph
The Alzheimer’s drug donanemab has shown promising results in a major clinical trial, raising hopes that it can slow the progression of the most common form of dementia. Developed by Eli Lilly, donanemab is an antibody therapy that targets abnormal clumps of the protein beta-amyloid, which are associated with Alzheimer’s disease. The drug works by binding to these plaques and removing them from the brain.
Although donanemab is not a cure, it has demonstrated the ability to clear approximately 90% of amyloid plaque from the brain. By removing this toxic protein early in the disease process, the drug has been shown to reduce brain damage and slow the rate of cognitive decline in patients. While it does not result in improvements, it has been found to delay deterioration compared to a control group that received a placebo.
UNDERSTANDING THE NEW DRUG – DONANEMAB
Although donanemab is not a cure, it has demonstrated the ability to clear approximately 90% of amyloid plaque from the brain. By removing this toxic protein early in the disease process, the drug has been shown to reduce brain damage and slow the rate of cognitive decline in patients. While it does not result in improvements, it has been found to delay deterioration compared to a control group that received a placebo
Rapid Action and Brain Plaque Reduction
The effectiveness of donanemab was observed to be more significant in patients in the early stages of the disease who had low levels of another harmful protein called tau in their brains. The results indicate that removing amyloid before tau spreads is crucial. Donanemab is administered through intravenous infusion every four weeks, and patients require regular brain scans to monitor for potential side effects, including brain swelling and bleeding.
Effective, but Not a Cure
Although donanemab is not a cure, it has demonstrated the ability to clear approximately 90% of amyloid plaque from the brain. By removing this toxic protein early in the disease process, the drug has been shown to reduce brain damage and slow the rate of cognitive decline in patients. While it does not result in improvements, it has been found to delay deterioration compared to a control group that received a placebo.
Potential Benefits for Early-Stage Patients
The effectiveness of donanemab was observed to be more significant in patients in the early stages of the disease who had low levels of another harmful protein called tau in their brains. The results indicate that removing amyloid before tau spreads is crucial. Donanemab is administered through intravenous infusion every four weeks, and patients require regular brain scans to monitor for potential side effects, including brain swelling and bleeding.
Similar Drugs in the Market
It is worth noting that donanemab is not the only drug of its kind. Lecanemab, developed by Eisai, is another amyloid-targeting antibody therapy that works similarly to donanemab. The US Food and Drug Administration (FDA) granted accelerated approval to lecanemab earlier this year, while European and UK regulators are still reviewing the drug. Another approved drug, aducanumab, has faced concerns regarding cost and effectiveness, limiting its widespread use.
A Cocktail Approach for Dementia Treatment
While these drugs represent a breakthrough in directly affecting the progression of Alzheimer’s disease, they have modest effects. Many scientists believe that a combination of drugs targeting different aspects of the disease process will be necessary to halt cognitive decline effectively.
Risks and Side Effects
It’s important to acknowledge the risks associated with donanemab. Significant side effects, including brain swelling and bleeding, have been observed in patients, although serious problems are rare. During the trial, a small number of participants, both in the donanemab group and the control group, experienced fatal outcomes.
Reference: Ian Sample Science editor – The Guardian NIA statement on donanemab results: More alzheimer’s research progress (no date) National Institute on Aging. Available at: https://www.nia. nih.gov/news/nia-statement-donanemab-resultsmore-alzheimers-research-progress (Accessed: 22 September 2023).
Smyth, J. (2023) Two alzheimer’s drugs offer hope to patients after decades of waiting, Financial Times. Available at: https://www.ft.com/content/ b18aefc1-ccbc-442e-a23c-117f27826d71 (Accessed: 22 September 2023).
The Alzheimer’s drug donanemab has shown promising results in a major clinical trial, raising hopes that it can slow the progression of the most common form of dementia. Developed by Eli Lilly, donanemab is an antibody therapy that targets abnormal clumps of the protein beta-amyloid, which are associated with Alzheimer’s disease. The drug works by binding to these plaques and removing them from the brain.
Although donanemab is not a cure, it has demonstrated the ability to clear approximately 90% of amyloid plaque from the brain. By removing this toxic protein early in the disease process, the drug has been shown to reduce brain damage and slow the rate of cognitive decline in patients. While it does not result in improvements, it has been found to delay deterioration compared to a control group that received a placebo.
UNDERSTANDING THE NEW DRUG – DONANEMAB
Although donanemab is not a cure, it has demonstrated the ability to clear approximately 90% of amyloid plaque from the brain. By removing this toxic protein early in the disease process, the drug has been shown to reduce brain damage and slow the rate of cognitive decline in patients. While it does not result in improvements, it has been found to delay deterioration compared to a control group that received a placebo
Rapid Action and Brain Plaque Reduction
The effectiveness of donanemab was observed to be more significant in patients in the early stages of the disease who had low levels of another harmful protein called tau in their brains. The results indicate that removing amyloid before tau spreads is crucial. Donanemab is administered through intravenous infusion every four weeks, and patients require regular brain scans to monitor for potential side effects, including brain swelling and bleeding.
Effective, but Not a Cure
Although donanemab is not a cure, it has demonstrated the ability to clear approximately 90% of amyloid plaque from the brain. By removing this toxic protein early in the disease process, the drug has been shown to reduce brain damage and slow the rate of cognitive decline in patients. While it does not result in improvements, it has been found to delay deterioration compared to a control group that received a placebo.
Potential Benefits for Early-Stage Patients
The effectiveness of donanemab was observed to be more significant in patients in the early stages of the disease who had low levels of another harmful protein called tau in their brains. The results indicate that removing amyloid before tau spreads is crucial. Donanemab is administered through intravenous infusion every four weeks, and patients require regular brain scans to monitor for potential side effects, including brain swelling and bleeding.
Similar Drugs in the Market
It is worth noting that donanemab is not the only drug of its kind. Lecanemab, developed by Eisai, is another amyloid-targeting antibody therapy that works similarly to donanemab. The US Food and Drug Administration (FDA) granted accelerated approval to lecanemab earlier this year, while European and UK regulators are still reviewing the drug. Another approved drug, aducanumab, has faced concerns regarding cost and effectiveness, limiting its widespread use.
A Cocktail Approach for Dementia Treatment
While these drugs represent a breakthrough in directly affecting the progression of Alzheimer’s disease, they have modest effects. Many scientists believe that a combination of drugs targeting different aspects of the disease process will be necessary to halt cognitive decline effectively.
Risks and Side Effects
It’s important to acknowledge the risks associated with donanemab. Significant side effects, including brain swelling and bleeding, have been observed in patients, although serious problems are rare. During the trial, a small number of participants, both in the donanemab group and the control group, experienced fatal outcomes.
Reference: Ian Sample Science editor – The Guardian NIA statement on donanemab results: More alzheimer’s research progress (no date) National Institute on Aging. Available at: https://www.nia. nih.gov/news/nia-statement-donanemab-resultsmore-alzheimers-research-progress (Accessed: 22 September 2023).
Smyth, J. (2023) Two alzheimer’s drugs offer hope to patients after decades of waiting, Financial Times. Available at: https://www.ft.com/content/ b18aefc1-ccbc-442e-a23c-117f27826d71 (Accessed: 22 September 2023).
